These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1010 related articles for article (PubMed ID: 30971826)

  • 1. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
    Behan FM; Iorio F; Picco G; Gonçalves E; Beaver CM; Migliardi G; Santos R; Rao Y; Sassi F; Pinnelli M; Ansari R; Harper S; Jackson DA; McRae R; Pooley R; Wilkinson P; van der Meer D; Dow D; Buser-Doepner C; Bertotti A; Trusolino L; Stronach EA; Saez-Rodriguez J; Yusa K; Garnett MJ
    Nature; 2019 Apr; 568(7753):511-516. PubMed ID: 30971826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WRN helicase is a synthetic lethal target in microsatellite unstable cancers.
    Chan EM; Shibue T; McFarland JM; Gaeta B; Ghandi M; Dumont N; Gonzalez A; McPartlan JS; Li T; Zhang Y; Bin Liu J; Lazaro JB; Gu P; Piett CG; Apffel A; Ali SO; Deasy R; Keskula P; Ng RWS; Roberts EA; Reznichenko E; Leung L; Alimova M; Schenone M; Islam M; Maruvka YE; Liu Y; Roper J; Raghavan S; Giannakis M; Tseng YY; Nagel ZD; D'Andrea A; Root DE; Boehm JS; Getz G; Chang S; Golub TR; Tsherniak A; Vazquez F; Bass AJ
    Nature; 2019 Apr; 568(7753):551-556. PubMed ID: 30971823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. To Discover the Efficient and Novel Drug Targets in Human Cancers Using CRISPR/Cas Screening and Databases.
    Onishi I; Yamamoto K; Kinowaki Y; Kitagawa M; Kurata M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Project Score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets.
    Dwane L; Behan FM; Gonçalves E; Lightfoot H; Yang W; van der Meer D; Shepherd R; Pignatelli M; Iorio F; Garnett MJ
    Nucleic Acids Res; 2021 Jan; 49(D1):D1365-D1372. PubMed ID: 33068406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets.
    Dempster JM; Pacini C; Pantel S; Behan FM; Green T; Krill-Burger J; Beaver CM; Younger ST; Zhivich V; Najgebauer H; Allen F; Gonçalves E; Shepherd R; Doench JG; Yusa K; Vazquez F; Parts L; Boehm JS; Golub TR; Hahn WC; Root DE; Garnett MJ; Tsherniak A; Iorio F
    Nat Commun; 2019 Dec; 10(1):5817. PubMed ID: 31862961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic Lethality and Cancer - Penetrance as the Major Barrier.
    Ryan CJ; Bajrami I; Lord CJ
    Trends Cancer; 2018 Oct; 4(10):671-683. PubMed ID: 30292351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR screen in mechanism and target discovery for cancer immunotherapy.
    Liu D; Zhao X; Tang A; Xu X; Liu S; Zha L; Ma W; Zheng J; Shi M
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188378. PubMed ID: 32413572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.
    Ferretti S; Hamon J; de Kanter R; Scheufler C; Andraos-Rey R; Barbe S; Bechter E; Blank J; Bordas V; Dammassa E; Decker A; Di Nanni N; Dourdoigne M; Gavioli E; Hattenberger M; Heuser A; Hemmerlin C; Hinrichs J; Kerr G; Laborde L; Jaco I; Núñez EJ; Martus HJ; Quadt C; Reschke M; Romanet V; Schaeffer F; Schoepfer J; Schrapp M; Strang R; Voshol H; Wartmann M; Welly S; Zécri F; Hofmann F; Möbitz H; Cortés-Cros M
    Nature; 2024 May; 629(8011):443-449. PubMed ID: 38658754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide CRISPR screens for the identification of therapeutic targets for cancer treatment.
    Xue VW; Wong SCC; Cho WCS
    Expert Opin Ther Targets; 2020 Nov; 24(11):1147-1158. PubMed ID: 32893711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9 Editing to Facilitate and Expand Drug Discovery.
    Robert F; Huang S; Pelletier J
    Curr Gene Ther; 2017; 17(4):275-285. PubMed ID: 29173168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Genomics for Cancer Drug Target Discovery.
    Haley B; Roudnicky F
    Cancer Cell; 2020 Jul; 38(1):31-43. PubMed ID: 32442401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization.
    Pacini C; Duncan E; Gonçalves E; Gilbert J; Bhosle S; Horswell S; Karakoc E; Lightfoot H; Curry E; Muyas F; Bouaboula M; Pedamallu CS; Cortes-Ciriano I; Behan FM; Zalmas LP; Barthorpe A; Francies H; Rowley S; Pollard J; Beltrao P; Parts L; Iorio F; Garnett MJ
    Cancer Cell; 2024 Feb; 42(2):301-316.e9. PubMed ID: 38215750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9 for cancer research and therapy.
    Zhan T; Rindtorff N; Betge J; Ebert MP; Boutros M
    Semin Cancer Biol; 2019 Apr; 55():106-119. PubMed ID: 29673923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal.
    Krill-Burger JM; Dempster JM; Borah AA; Paolella BR; Root DE; Golub TR; Boehm JS; Hahn WC; McFarland JM; Vazquez F; Tsherniak A
    Genome Biol; 2023 Aug; 24(1):192. PubMed ID: 37612728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying synthetic lethal targets using CRISPR/Cas9 system.
    Dhanjal JK; Radhakrishnan N; Sundar D
    Methods; 2017 Dec; 131():66-73. PubMed ID: 28710008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. InVivo Cancer-Based Functional Genomics.
    Li C; Kasinski AL
    Trends Cancer; 2020 Dec; 6(12):1002-1017. PubMed ID: 32828714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of disease-specific and CRISPR/Cas9-mediated gene-corrected iPS cells from a patient with adult progeria Werner syndrome.
    Kato H; Maezawa Y; Ouchi Y; Takayama N; Sone M; Sone K; Takada-Watanabe A; Tsujimura K; Koshizaka M; Nagasawa S; Saitoh H; Ohtaka M; Nakanishi M; Tahara H; Shimamoto A; Iwama A; Eto K; Yokote K
    Stem Cell Res; 2021 May; 53():102360. PubMed ID: 34087989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A CRISPR Way to Identify Cancer Targets.
    Hahn WC
    N Engl J Med; 2019 Jun; 380(25):2475-2477. PubMed ID: 31216404
    [No Abstract]   [Full Text] [Related]  

  • 19. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
    Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
    Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains.
    Shi J; Wang E; Milazzo JP; Wang Z; Kinney JB; Vakoc CR
    Nat Biotechnol; 2015 Jun; 33(6):661-7. PubMed ID: 25961408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.